ArticleiScience2026
Role of NR2F2-mediated reprogramming of endothelial cells in glioblastoma progression.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GATA2-driven ZNF486-JAM2 activation collaboratively counteracts epithelial-mesenchymal transition andFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM), a malignant brain tumor, is characterized by a high recurrence rate and poor overall survival. Therefore, understanding the causes of recurrence and identifying strategies for its prevention are crucial. To identify the characteristics of recurrent tumor samples and the molecular mechanisms of tumor progression, we conducted a longitudinal analysis of GBM using single-cell transcriptomics and clinical data from the Chinese Glioma Genome Atlas (CGGA). Compared to the primary tumor, recurrent GBM samples showed a more immunosuppressive environment. We identified an endothelial cell subpopulation, Edo4, that is characterized by high endothelial-to-mesenchymal transition (EMT) and is correlated with poor prognosis in recurrent tumors. It was regulated by the NR2F2 transcription factor specifically in the recurrent GBM samples. Cell-cell interaction analysis revealed that pericytes affect endothelial cell migration through the JAM2-(ITGA3+ITGB1) ligand-receptor axis, promoting GBM progression. Targeting the Edo4 cell cluster and the JAM2-(ITGA3+ITGB1) ligand-receptor pair may be a promising strategy to prevent GBM recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.